Should I buy or sell Alkermes stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks .

What is Alkermes' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price objectives for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they anticipate the company's stock price to reach $32.29 in the next year. This suggests a possible upside of 20.1% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts .

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 at the start of the year. Since then, ALKS stock has increased by 2.9% and is now trading at $26.88. View the best growth stocks for 2023 here .

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our ALKS earnings forecast .

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) released its earnings results on Wednesday, October, 25th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%.

What ETFs hold Alkermes' stock?

ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) , Subversive Mental Health ETF (SANE) , iShares Neuroscience and Healthcare ETF (IBRN) , Horizon Kinetics Medical ETF (MEDX) , ALPS Medical Breakthroughs ETF (SBIO) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB) .

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com . Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD) , Netflix (NFLX) , Pfizer (PFE) , NVIDIA (NVDA) , AbbVie (ABBV) , Starbucks (SBUX) , Intel (INTC) , Johnson & Johnson (JNJ) and Tesla (TSLA) .

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson , Cato T Laurencin , Christian Todd Nichols , Craig C Hopkinson, Craig C Hopkinson , David Joseph Gaffin , David W Anstice , Emily Peterson Alva , Iain Michael Brown , Michael J Landine , Nancy Wysenski , Richard F Pops , Shane Cooke and Wendy L Dixon . View institutional ownership trends .

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics. Read More

Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$26.88

+0.55 (+2.09%)

(As of 12/5/2023 ET)

Compare

Today's Range: $26.10
▼
$26.95
50-Day Range: $23.37
▼
$28.68
52-Week Range: $22.01
▼
$33.71

Volume: 3.07 million shs
Average Volume: 1.60 million shs
Market Capitalization: $4.49 billion

P/E Ratio: 21.68
Dividend Yield: N/A
Price Target: $32.29

Alkermes MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 20.1% Upside
$32.29 Price Target
Short Interest: Healthy
4.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.17
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 59.26%
From $1.08 to $1.72 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

62nd out of 948 stocks

Pharmaceutical Preparations Industry

14th out of 421 stocks

3.3

Analyst's Opinion

Consensus Rating
Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.29, Alkermes has a forecasted upside of 20.1% from its current price of $26.88.
Amount of Analyst Coverage
Alkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.77% of the outstanding shares of Alkermes have been sold short.
Short Interest Ratio / Days to Cover
Alkermes has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Alkermes has recently decreased by 0.38%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Alkermes does not currently pay a dividend.
Dividend Growth
Alkermes does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alkermes is -1.17.

2.6

News and Social Media Coverage

News Sentiment
Alkermes has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Alkermes this week, compared to 4 articles on an average week.
Search Interest
10 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alkermes insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.76% of the stock of Alkermes is held by insiders.
Percentage Held by Institutions
95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Alkermes are expected to grow by 59.26% in the coming year, from $1.08 to $1.72 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alkermes is 21.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.42.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alkermes is 21.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.76.
Price to Book Value per Share Ratio
Alkermes has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALKS Stock News Headlines

December 2, 2023 | americanbankingnews.com

Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages

November 26, 2023 | americanbankingnews.com

Alkermes (NASDAQ:ALKS) Lifted to "Strong-Buy" at StockNews.com

December 6, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

November 24, 2023 | finance.yahoo.com

Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?

November 20, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), Alkermes (ALKS) and Olink Holding (OLK)

November 17, 2023 | bizjournals.com

Why Alkermes spun out an oncology company, whose shares have plummeted

November 16, 2023 | finanznachrichten.de

Alkermes plc: Alkermes Completes Separation of Oncology Business into Mural Oncology plc

November 15, 2023 | finanznachrichten.de

Alkermes Completes Separation Of Oncology Business; Updates 2023 Guidance

December 6, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

November 15, 2023 | finance.yahoo.com

Alkermes Completes Separation of Oncology Business

November 14, 2023 | finance.yahoo.com

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

November 13, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF), Alkermes (ALKS) and Dexcom (DXCM)

November 10, 2023 | seekingalpha.com

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate

November 8, 2023 | seekingalpha.com

Alkermes' OX2R Agonist For Narcolepsy Peaks Interest Amidst Strong Q3 Earnings

November 7, 2023 | stocknews.com

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

November 7, 2023 | finance.yahoo.com

Alkermes to Participate in the Jefferies London Healthcare Conference

October 31, 2023 | finance.yahoo.com

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

October 30, 2023 | stocknews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

October 30, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Blueprint Medicines (BPMC)

October 27, 2023 | msn.com

Piper Sandler Maintains Alkermes (ALKS) Overweight Recommendation

October 27, 2023 | msn.com

Mizuho Maintains Alkermes (ALKS) Buy Recommendation

October 26, 2023 | finance.yahoo.com

Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript

October 26, 2023 | finance.yahoo.com

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

October 25, 2023 | markets.businessinsider.com

Hold Rating on Alkermes’ Stock: Leerink Partners Cites Early Efficacy Data and Tolerability Concerns for ALKS2680 Narcolepsy Treatment

October 25, 2023 | finanznachrichten.de

Alkermes Turns To Profit In Q3, Beats Estimates; Backs Full-year Outlook

October 25, 2023 | finance.yahoo.com

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

October 25, 2023 | msn.com

Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook

See More Headlines

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/25/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALKS
CUSIP: G0176710
CIK: 1520262
Web: www.alkermes.com
Phone: (531) 772-8000
Fax: 781-890-0524
Employees: 2,280
Year Founded: 1987

Price Target and Rating

Average Stock Price Target: $32.29
High Stock Price Target: $35.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +20.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.24
Trailing P/E Ratio: 21.68
Forward P/E Ratio: 24.89
P/E Growth: N/A
Net Income: $-158,270,000.00
Net Margins: 13.50%
Pretax Margin: 13.68%
Return on Equity: 11.41%
Return on Assets: 6.40%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 2.91
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: $1.11 billion
Price / Sales: 4.03
Cash Flow: $0.28 per share
Price / Cash Flow: 96.25
Book Value: $6.35 per share
Price / Book: 4.23

Miscellaneous

Outstanding Shares: 166,880,000
Free Float: 158,937,000
Market Cap: $4.49 billion
Optionable: Optionable
Beta: 0.64

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Richard F. Pops (Age 61)
Chairman & CEO
Comp: $2.3M
Mr. Iain Michael Brown (Age 54)
Senior VP & CFO
Comp: $867.75k
Mr. Blair C. Jackson (Age 50)
Executive VP & COO
Comp: $1.05M
Mr. David Joseph Gaffin (Age 51)
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
Comp: $1.08M
Dr. Craig C. Hopkinson M.D. (Age 55)
Executive VP of Research & Development and Chief Medical Officer
Comp: $1.12M
Dr. Floyd E. Bloom M.D. (Age 86)
Founder
Comp: $57.73k
Mr. Thomas Harvey
Chief Information Officer & Senior VP of IT
Ms. Sandra Coombs
Senior Vice President of Corporate Affairs & Investor Relations
Mr. Michael J. Landine (Age 69)
Senior VP of Corporate Development & Chief Risk Officer
Comp: $750.46k
Mr. Stephen Schiavo
Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings or view top-rated stocks.
What is Alkermes' stock price target for 2024?: 7 Wall Street research analysts have issued 12 month price objectives for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they anticipate the company's stock price to reach $32.29 in the next year. This suggests a possible upside of 20.1% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.
How have ALKS shares performed in 2023?: Alkermes' stock was trading at $26.13 at the start of the year. Since then, ALKS stock has increased by 2.9% and is now trading at $26.88.
View the best growth stocks for 2023 here.
When is Alkermes' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our ALKS earnings forecast.
How were Alkermes' earnings last quarter?: Alkermes plc (NASDAQ:ALKS) released its earnings results on Wednesday, October, 25th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%.
What ETFs hold Alkermes' stock?: ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB).

What guidance has Alkermes issued on next quarter's earnings?: Alkermes issued an update on its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58.
What is Richard F. Pops' approval rating as Alkermes' CEO?: 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.
What other stocks do shareholders of Alkermes own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).
Who are Alkermes' major shareholders?: Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends.
How do I buy shares of Alkermes?: Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Alkermes have any subsidiaries?: The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More

This page (NASDAQ:ALKS) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial